



The superior chronic pain therapy that leaves patients

SPEECHLESS.


nevro®
HF10™ THERAPY

WE BELIEVE

TRUE INNOVATION TRANSFORMS MORE LIVES.

10 years of clinical development has resulted in a superior therapy that represents a significant advance in spinal cord stimulation (SCS).

2006	2007	2008	2009	2010
Nevro is founded	Stanford University <ul style="list-style-type: none">• Breakthrough animal studies	University of California, Davis <ul style="list-style-type: none">• Validation in large animal model	U.S. Feasibility Study <ul style="list-style-type: none">• First comparison of high-frequency and traditional SCS	European Study (SENZA-EU) is initiated CE mark granted for HF10™ therapy

We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of SCS.



We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: **a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.¹**

2011

**Commercial launch
of HF10 therapy
in Europe
and Australia**

2012

**First pivotal
randomized, controlled
trial of an SCS system
initiated (SENZA-RCT)**

2013

**SENZA-RCT
enrollment completed
SENZA-EU 24-month
results published**

2014

**SENZA-RCT 12-month
follow-up completed
NEURO listed on
NY Stock Exchange

SENZA-RCT presented
at Groundbreaking
Clinical Trial Results
session at 18th Annual
North American
Neuromodulation
Society Conference**

2015

**FDA
APPROVAL**

HF10 THERAPY IS BACKED BY BEST-IN-CLASS CLINICAL EVIDENCE.

COMPARATIVE, FEASIBILITY

5 centers, 24 patients trialed with both traditional SCS and HF10 therapy

Demonstrated safety and efficacy in humans (acute follow-up)

88% of patients preferred high-frequency SCS

Published in *Neuromodulation*

2009
**U.S. FEASIBILITY
STUDY**

PROSPECTIVE, LONG-TERM

2 centers, 72 patients implanted

Demonstrated long-term safety and efficacy for both back pain and leg pain (24-month follow-up)

Published in *Pain Medicine*

2013
**EUROPEAN
MULTICENTER,
24-MONTH STUDY
(SENZA-EU)**

RANDOMIZED, CONTROLLED

10 U.S. centers, 241 enrolled, 198 randomized, 171 implanted

Randomized, controlled trial compared HF10 therapy with traditional SCS

Demonstrated superiority at all primary and secondary endpoints vs traditional SCS (12-month follow-up)

Published in *Anesthesiology*

2015
**U.S. PIVOTAL STUDY
(SENZA-RCT)**

SENZA-RCT.
THE FIRST
MULTICENTER,
PROSPECTIVE,
RANDOMIZED,
CONTROLLED
PIVOTAL STUDY
OF AN SCS
SYSTEM.

THE LARGEST STUDY IN SCS HISTORY
PROVIDING COMPARATIVE LEVEL I
EVIDENCE FOR BACK PAIN AND LEG PAIN.

**SENZA-RCT VALIDATES TRADITIONAL SCS AND DEMONSTRATES SUPERIORITY
OF HF10 THERAPY.**

- + First study to directly compare SCS technologies
- + First randomized study to enroll patients with back pain and leg pain
- + Largest randomized, controlled study for back pain and leg pain: 241 participants enrolled, 198 randomized, 171 implanted
- + First SCS study to report on 100% of patients to 12 months
- + Designed in consultation with and monitored by the FDA
- + Directly compared HF10 therapy to traditional SCS—with each company supporting their respective device programming

**HF10 THERAPY IS SUPERIOR TO TRADITIONAL SCS FOR ALL
PRIMARY AND SECONDARY ENDPOINTS.¹**



When

TEARS OF JOY

flow instead of words,
the results speak for her.


79%

of patients achieved
≥50% pain relief for severe
back pain and leg pain.¹

HF10 THERAPY DELIVERED SUPERIOR BACK PAIN AND LEG PAIN RESPONSE.¹


SUPERIOR BACK PAIN RESPONSE

≥50% Reduction in VAS Score, p-value <0.001, n=171




SUPERIOR LEG PAIN RESPONSE

≥50% Reduction in VAS Score, p-value <0.001, n=171




HF10 THERAPY
DELIVERED
SUPERIOR
REDUCTION IN
BOTH BACK PAIN
AND LEG PAIN AT
ALL MEASURED
TIME POINTS!

SUPERIOR BACK PAIN RELIEF




SUPERIOR LEG PAIN RELIEF



All he feels is
HAPPINESS.

**HF10 THERAPY. THE ONLY
SCS THERAPY INDICATED
TO DELIVER PAIN RELIEF
WITHOUT PARESTHESIA.¹**

**PATIENTS REPORTING UNCOMFORTABLE STIMULATION
WITHIN 12 MONTHS¹**



QUALITY OF LIFE BENEFITS

- Eliminates restrictions on driving and sleeping
- Improves patient satisfaction

PROCEDURE BENEFITS


- Eliminates intraoperative paresthesia mapping
- Consistent anatomical lead placement (T8-T11) for back pain and leg pain



HF10 THERAPY IS CONSISTENTLY SUPERIOR FOR TREATING BOTH BACK PAIN AND LEG PAIN.¹⁻⁴


PUBLISHED PROSPECTIVE STUDY COMPARISON

SUPERIOR BACK PAIN RESPONSE




ASSESSMENT (12 MONTHS)

SUPERIOR LEG PAIN RESPONSE




ASSESSMENT (12 MONTHS)

SUPERIOR BACK PAIN RELIEF



ASSESSMENT (12 MONTHS)

SUPERIOR LEG PAIN RELIEF




ASSESSMENT (12 MONTHS)

REPRODUCIBILITY OF RESULTS WITH HF10 THERAPY SPEAKS VOLUMES.^{1,2}

OUTCOMES FROM SENZA-RCT AND SENZA-EU DEMONSTRATE CLINICAL CONSISTENCY.

CONSISTENT REDUCTION IN BACK PAIN



CONSISTENT TRIAL-TO-PERMANENT THERAPY CONVERSION RATES*

- SENZA-RCT: 88%
- SENZA-EU: 88%

CONSISTENT ODI[†] REDUCTION

- SENZA-RCT: 16-point reduction
- SENZA-EU: 17-point reduction

HF10 THERAPY ACHIEVED SUPERIOR OUTCOMES WHILE DEMONSTRATING EQUIVALENT SAFETY TO TRADITIONAL SCS.¹

*Using >50% reduction in VAS score.

[†]Oswestry disability index.

HF10 THERAPY IS PROVEN TO PROVIDE MORE PATIENTS MORE RELIEF IN MORE PAIN AREAS— WITH NO PARESTHESIA.¹


BEST-IN-CLASS TECHNOLOGY

The only IPG indicated to deliver paresthesia-free therapy

The only SCS system that is 1.5 and 3 Tesla MRI compatible for head and extremity scans

The only IPG with 10-year-plus battery life at 10 kHz

The only IPG that delivers HF10 therapy



All patients do not respond the same way to spinal cord stimulation (SCS) and experiences may vary. Patients should consult a physician to understand the potential benefits and risks of treatment with SCS.

1. Kapural L, et al. Comparison of 10 kHz high-frequency SCS to traditional low-frequency SCS: the SENZA-RCT U.S. pivotal study. Presented at: 18th Annual North American Neuromodulation Society Conference; December 11-14, 2014; Las Vegas, NV.
2. Al-Kaisy A, Van Buyten J-P, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. *Pain Med.* 2014;15:347-354.
3. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. *Neurosurgery.* 2008;63:762-770.
4. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. *Pain.* 2007;132:179-188.

CE
0086 Effective
4 May 2010

USA

EC REP

MDSS GMBH
Schiffgraben 41
D-30175 Hannover,
Germany

Australian Sponsor:
Emergo Asia Pacific Pty Ltd
201 Sussex Street, Darling Park,
Tower II, Level 20
Sydney, NSW 2000
Australia

HF10 THERAPY PARAMETERS

Parameter	Specification
System type	Constant current
Frequency (Hz)	10,000
Maximum number of electrodes	16
MRI compatibility (scan location)	Head and extremity
MRI compatibility (scanner)	1.5T and 3T
Device battery life at 10 kHz (years)	10+
Average daily charging time (minutes)	45
Battery overdischarge protection	Yes
Field-upgradable software	Yes
RF wireless range (inches)	60

See Senza® system catalog for ordering numbers and detailed specifications.

TALK TO YOUR NEVRO® REPRESENTATIVE
ABOUT A START-UP PLAN.



Nevro Corp.

1800 Bridge Parkway
Redwood City, CA 94065 USA
www.nevro.com
Tel. 1.650.251.0005
Toll-free 1.888.956.3876

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.
©2015 Nevro Corp. All Rights Reserved.
2015031 Rev. B